Clinical Trial Update: Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pembrolizumab in combination with low-dose PFas neoadjuvant treatment for locally advanced head and neck squamous cell carci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Zhejiang Provincial People's Hospital | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING